⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMY News
Bristol-Myers Squibb Co.
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
businesswire.com
BMY
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
businesswire.com
BMY
Active Pharmaceutical Ingredients (API) Market 2026-2034: Global Size, Share, Growth and Company Analysis | Generics, Biologics and Outsourcing Drive Value to $400.94 Billion
globenewswire.com
TEVA
BIIB
PFE
BMY
LLY
MRK
ABBV
On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative
prnewswire.com
BMY
Global Pharmacovigilance Market - Forecast 2026-2032 | AI, Cloud Platforms, and Outsourcing Fuel 16.34% CAGR, Creating a USD 34.17 Billion Opportunity by 2032
globenewswire.com
BMY
GSK
IBM
IQV
ORCL
PFE
Venous Thromboembolism - 7MM Market Insights, Epidemiology, and Market Forecast - 2036 | Rising VTE Burden and Factor XI Innovation Drive Growth Opportunities
globenewswire.com
BMY
REGN
PFE
Large Volume Wearable Injectors Market by Device Type, Usability, Therapeutic Area, and Region - Forecast to 2035 | Home-Based Delivery Drives 7.5% CAGR to USD 31.4 Billion
globenewswire.com
WST
LULU
AMGN
BMY
REGN
LLY
MDT
Global Synthetic Biology Market Size, Share, Growth Trends, and Forecast 2026-2035 | CRISPR, AI, and Biomanufacturing Drive 17.5% CAGR to USD 128.1 Billion
globenewswire.com
TWST
TMO
GEVO
BMY
Arteriosclerosis Obliterans Market Shows Promising Growth Prospects During the Forecast Period (2026-2036) Amid Evolving Treatment Landscape | DelveInsight
prnewswire.com
LLY
REGN
LSTA
ABT
PFE
JNJ
MRK
BMY
AZN
NVS
AMGN
GILD
BIIB
Autologous Cell Therapy Market Size, Share, and Outlook - Growth Analysis and Forecast, 2026-2035 | CAR-T and Personalized Oncology Fuel 19.40% CAGR to USD 54.83 Billion
globenewswire.com
AZN
GILD
JNJ
BMY
VERI
LCTX